Who is sponsoring NCT00087958?

NCT00087958 is sponsored by Sanofi.

What condition does NCT00087958 study?

NCT00087958 studies Breast Cancer.

What is the status of NCT00087958?

NCT00087958 is currently COMPLETED.

Last reviewed 2009-04-30 · How we verify

Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine

NCT00087958 Phase 2 COMPLETED

The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

Details

Lead sponsor	Sanofi
Phase	Phase 2
Status	COMPLETED
Enrolment	168
Start date	2004-08
Completion	2009-04

Conditions

Breast Cancer

Interventions

XRP9881

Primary outcomes

Objective response rate as assessed by Response Evaluation Criteria in Solid Tumors

Countries

United States, Argentina, Belgium, Canada, Colombia, Denmark, France, Germany, Italy, Netherlands, South Africa, South Korea, Spain, Switzerland, Turkey (Türkiye)